PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Market Cap | 784M 910M 722M 678M 1.27B 86B 1.29B 8.53B 3.32B 42.12B 3.41B 3.34B 146B | P/E Ratio 2026 * |
36.1x | P/E Ratio 2027 * | 30.7x |
|---|---|---|---|---|---|
| Enterprise Value | 752M 873M 693M 650M 1.22B 82.51B 1.23B 8.18B 3.19B 40.4B 3.27B 3.21B 140B | EV / Sales 2026 * |
1.86x | EV / Sales 2027 * | 1.56x |
| Free-Float |
98.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 2025-03-03 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 2025-09-30 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.13% | -1.33% | +39.86% | +152.28% | 1,007B | |
| -0.49% | -0.97% | +51.21% | +42.91% | 567B | |
| +0.12% | -1.62% | +16.19% | +59.95% | 392B | |
| -0.80% | +1.05% | +20.91% | +18.37% | 328B | |
| -0.43% | +1.12% | +24.21% | +31.89% | 277B | |
| +0.64% | -2.55% | +22.80% | +12.69% | 275B | |
| -1.86% | +4.01% | -43.73% | -49.21% | 196B | |
| -0.83% | +1.04% | +17.79% | +51.59% | 189B | |
| +2.06% | +0.94% | +14.30% | +60.64% | 154B | |
| Average | -0.24% | +0.33% | +18.17% | +42.35% | 376.23B | |
| Weighted average by Cap. | -0.26% | -0.03% | +27.28% | +67.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 404M 468M 372M 349M 655M 44.27B 662M 4.39B 1.71B 21.68B 1.76B 1.72B 75.13B | 448M 520M 412M 387M 727M 49.13B 735M 4.87B 1.9B 24.06B 1.95B 1.91B 83.37B |
| Net income | 43.03M 49.93M 39.62M 37.2M 69.85M 4.72B 70.59M 468M 182M 2.31B 187M 183M 8.01B | 45.58M 52.89M 41.97M 39.4M 73.98M 5B 74.76M 496M 193M 2.45B 198M 194M 8.49B |
| Net Debt | -31.88M -37M -29.36M -27.57M -51.75M -3.5B -52.3M -347M -135M -1.71B -139M -136M -5.94B | -85.08M -98.72M -78.34M -73.56M -138M -9.33B -140M -926M -361M -4.57B -370M -363M -15.84B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
